查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1866499

介入心臟病学市场－2025-2030年预测

Interventional Cardiology Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

介入心臟病学市场预计将从 2025 年的 260.96 亿美元成长到 2030 年的 347.42 亿美元，复合年增长率为 5.89%。

由于微创手术的日益普及和心血管疾病（CVD）盛行率的上升，全球介入心臟病学市场预计将迎来强劲成长。介入心臟病学利用导管（插入体内的细长软管）治疗受损血管、狭窄动脉和其他心臟疾病，透过血管成形术和瓣膜修復/置换术等手术，为开胸手术提供了一种替代方案。导管类器械的技术进步提高了手术的精准度和病患疗效，进而推动了市场发展。然而，严格的器械核准监管要求以及高成本，尤其是在开发中国家经济体和欠发达经济体，都对市场扩张构成了挑战。

市场驱动因素

心血管疾病呈上升趋势

全球心血管疾病负担持续加重，是介入心臟病学市场的主要驱动力。心血管疾病（CVD）是全球主要死因之一，亟需先进的治疗方案，进而推动了对微创介入手术的需求。冠状动脉疾病和瓣膜性心臟病等疾病发病率的不断上升，促使人们采用导管介入手术，与传统手术相比，导管介入手术恢復更快，风险更低。

医疗设备创新

介入心臟病学器材的创新，例如新一代支架、球囊和影像导引导管，正显着推动市场成长。这些进步提高了手术的精准性、安全性和有效性，从而改善了复杂心血管疾病的治疗。改进的器械设计，例如生物可吸收支架和先进的瓣膜修復系统，正在拓展治疗选择，进一步刺激市场需求。

全球医疗保健成本不断上涨

全球医疗保健支出不断增长，尤其是在已开发经济体和新兴经济体，这推动了介入心臟病学市场的成长。医疗基础设施投资的增加以及先进医疗技术的普及，促进了微创手术的采用，刺激了对专业心臟病学设备的需求，并创造了新的市场机会。

市场限制

严格的监管要求

介入心臟病学器材的核准流程受到严格的监管审查，这可能会延迟产品上市并增加研发成本。遵守各地不同的标准，尤其是在北美和欧洲，对製造商来说是一项挑战，并可能减缓市场成长。

开发中国家国家的高成本

介入心臟病学手术和设备的高成本限制了开发中国家和欠发达经济体的医疗服务获取，这些地区的医疗预算和病患支付能力都较为有限。这种支付能力差距阻碍了高成长地区的市场渗透，并限制了整体扩张。

市场区隔与区域展望

从地理上看，北美和欧洲的介入心臟病学市场主导显着增长，这主要得益于先进的医疗保健体系、较高的心血管疾病（CVD）患病率以及健全的研发生态系统。亚太地区预计也将迎来显着成长，这主要得益于医疗保健投资的增加、疾病负担的加重以及中国和印度等国家先进疗法的可及性提高。

主要企业

介入心臟病学市场的主要企业包括Medtronic、史赛克、雅培、贝朗-梅尔松根公司、波士顿科学、科迪斯（康德乐）、爱德华生命科学、通用电气医疗集团、生物感测器国际集团和百多力公司。这些公司正专注于创新、策略伙伴关係和产品组合扩展，以保持其竞争优势。

产业展望

介入心臟病学市场预计将持续成长，主要受心血管疾病负担加重、技术进步和医疗保健投资增加的推动。儘管监管和成本方面的挑战依然存在，但该市场与微创趋势和亚太地区经济成长的契合预计将推动其显着扩张，为相关人员创造满足未被满足的医疗需求的机会。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及影响、新产品开发、竞争影响

分析范围

  • 历史资料（2022-2024 年）和预测资料（2025-2030 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

第五章 按器械类型介入心臟病学市场

  • 介绍
  • 支架
    • 药物释放型支架（DES）
    • 裸金属支架（BMS）
    • 生物可吸收支架
  • 导管
    • 诊断导管
    • 引导管
  • 经皮冠状动脉介入治疗（PTCA）球囊
    • 传统球囊血管成形术（POBA）球囊
    • 切割/球囊导管
    • 药物释放型球囊（DCB）
  • 动脉粥状硬化斑块切除术装置
  • 斑块调节装置
  • 导管导引线
  • 栓塞保护装置
  • 其他的

第六章 按应用分類的介入心臟病学市场

  • 介绍
  • 冠状动脉疾病
  • 瓣膜性心臟病
    • 经导管主动脉瓣置换术（TAVR）
    • 经导管二尖瓣瓣膜修復/置换术（TMVR）
  • 週边血管疾病
  • 结构性心臟疾病
    • 心房中膈缺损症（ASD）封堵术
    • 卵圆孔未闭合（PFO）封堵术
    • 左心耳封堵术（LAA封堵术）
  • 先天性心臟疾病

第七章介入心臟病学市场（依最终用户划分）

  • 介绍
  • 医院和诊所
  • 门诊手术中心（ASC）
  • 专业心臟中心

第八章：介入心臟病学市场区域分析

  • 介绍
  • 北美洲
    • 依设备类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 美国
      • 加拿大
      • 墨西哥
  • 南美洲
    • 依设备类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 依设备类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 依产品类型
    • 透过使用
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 依设备类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 中国
      • 日本
      • 印度
      • 韩国
      • 台湾
      • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十章：公司简介

  • Medtronic
  • Stryker
  • Abbott
  • B. Braun Melsungen AG
  • Boston Scientific Corporation
  • Cordis
  • Edwards Lifesciences Corporation
  • GE Healthcare
  • Biosensors International Group, Ltd.
  • Biotronik, Inc.

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061611750

The Interventional Cardiology Market is projected to expand from USD 26.096 billion in 2025 to USD 34.742 billion in 2030, registering a 5.89% compound annual growth rate (CAGR).

The global interventional cardiology market is poised for robust growth, driven by the increasing adoption of minimally invasive procedures and the rising prevalence of cardiovascular diseases (CVDs). Interventional cardiology utilizes catheters-thin, flexible tubes inserted into the body-to treat damaged vessels, narrowed arteries, and other heart conditions, offering alternatives to open surgery through procedures like angioplasty and valve repair or replacement. The market is supported by technological advancements in catheter-based devices, which enhance procedural precision and patient outcomes. However, stringent regulatory requirements for device approvals and the high cost of procedures, particularly in developing and underdeveloped economies, pose challenges to market expansion.

Market Drivers

Increasing Prevalence of Cardiovascular Diseases

The global burden of cardiovascular diseases remains a primary driver of the interventional cardiology market. As a leading cause of mortality worldwide, CVDs necessitate advanced treatment options, boosting demand for minimally invasive interventions. The growing incidence of conditions such as coronary artery disease and heart valve disorders is driving the adoption of catheter-based procedures, which offer reduced recovery times and lower risks compared to traditional surgery.

Technological Advancements in Devices

Innovations in interventional cardiology devices, including next-generation stents, balloons, and imaging-guided catheters, are significantly propelling market growth. These advancements improve procedural accuracy, safety, and efficacy, enabling better management of complex cardiovascular conditions. Enhanced device designs, such as bioresorbable stents and advanced valve repair systems, are expanding treatment options, further fueling market demand.

Increasing Health Expenditure Worldwide

Rising global healthcare expenditure, particularly in developed and emerging economies, is supporting the growth of the interventional cardiology market. Increased investments in healthcare infrastructure and access to advanced medical technologies are enabling wider adoption of minimally invasive procedures, driving demand for specialized cardiology devices and expanding market opportunities.

Market Restraints

Stringent Regulatory Requirements

The approval process for interventional cardiology devices is subject to rigorous regulatory scrutiny, which can delay market entry and increase development costs. Compliance with diverse regional standards, particularly in North America and Europe, poses challenges for manufacturers, potentially slowing market growth.

High Cost in Developing Economies

The high cost of interventional cardiology procedures and devices limits accessibility in developing and underdeveloped economies, where healthcare budgets and patient affordability are constrained. This affordability gap restricts market penetration in high-growth regions, hindering overall expansion.

Market Segmentation and Geographical Outlook

The interventional cardiology market is segmented by geography, with North America and Europe leading due to advanced healthcare systems, high CVD prevalence, and robust R&D ecosystems. Asia-Pacific is expected to exhibit significant growth, driven by rising healthcare investments, increasing disease burdens, and improving access to advanced treatments in countries like China and India.

Key Players

Major players in the interventional cardiology market include Medtronic, Stryker, Abbott, B. Braun Melsungen AG, Boston Scientific Corporation, Cordis (A Cardinal Health Company), Edwards Lifesciences Corporation, GE Healthcare, Biosensors International Group, Ltd., and Biotronik, Inc. These companies focus on innovation, strategic partnerships, and portfolio expansion to maintain competitive advantage.

Industry Outlook

The interventional cardiology market is set for sustained growth, driven by the rising CVD burden, technological advancements, and increasing healthcare investments. While regulatory and cost-related challenges persist, the market's alignment with minimally invasive trends and regional growth in Asia-Pacific positions it for significant expansion, offering opportunities for stakeholders to address unmet medical needs.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

By Device Type

  • Stents
  • Drug-Eluting Stents (DES)
  • Bare-Metal Stents (BMS)
  • Bioabsorbable Stents
  • Catheters
  • Diagnostic Catheters
  • Guiding Catheters
  • Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons
  • Plain Old Balloon Angioplasty (POBA) Balloons
  • Cutting/Scoring Balloons
  • Drug-Coated Balloons (DCB)
  • Atherectomy Devices
  • Plaque Modification Devices
  • Guidewires
  • Embolic Protection Devices
  • Others

By Application

  • Coronary Artery Disease
  • Heart Valve Disease
  • Transcatheter Aortic Valve Replacement (TAVR)
  • Transcatheter Mitral Valve Repair/Replacement (TMVR)
  • Peripheral Vascular Disease
  • Structural Heart Disease
  • Atrial Septal Defect (ASD) Closure
  • Patent Foramen Ovale (PFO) Closure
  • Left Atrial Appendage (LAA) Closure
  • Congenital Heart Defects

By End-User

  • Hospitals and Clinics
  • Ambulatory Surgery Centers (ASCs)
  • Specialty Cardiac Centers

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. INTERVENTIONAL CARDIOLOGY MARKET BY DEVICE TYPE

  • 5.1. Introduction
  • 5.2. Stents
    • 5.2.1. Drug-Eluting Stents (DES)
    • 5.2.2. Bare-Metal Stents (BMS)
    • 5.2.3. Bioabsorbable Stents
  • 5.3. Catheters
    • 5.3.1. Diagnostic Catheters
    • 5.3.2. Guiding Catheters
  • 5.4. Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons
    • 5.4.1. Plain Old Balloon Angioplasty (POBA) Balloons
    • 5.4.2. Cutting/Scoring Balloons
    • 5.4.3. Drug-Coated Balloons (DCB)
  • 5.5. Atherectomy Devices
  • 5.6. Plaque Modification Devices
  • 5.7. Guidewires
  • 5.8. Embolic Protection Devices
  • 5.9. Others

6. INTERVENTIONAL CARDIOLOGY MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Coronary Artery Disease
  • 6.3. Heart Valve Disease
    • 6.3.1. Transcatheter Aortic Valve Replacement (TAVR)
    • 6.3.2. Transcatheter Mitral Valve Repair/Replacement (TMVR)
  • 6.4. Peripheral Vascular Disease
  • 6.5. Structural Heart Disease
    • 6.5.1. Atrial Septal Defect (ASD) Closure
    • 6.5.2. Patent Foramen Ovale (PFO) Closure
    • 6.5.3. Left Atrial Appendage (LAA) Closure
  • 6.6. Congenital Heart Defects

7. INTERVENTIONAL CARDIOLOGY MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
  • 7.3. Ambulatory Surgery Centers (ASCs)
  • 7.4. Specialty Cardiac Centers

8. INTERVENTIONAL CARDIOLOGY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Device Type
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Device Type
    • 8.3.2. By Application
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Device Type
    • 8.4.2. By Application
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Product Type
    • 8.5.2. By Application
    • 8.5.3. By Country
      • 8.5.3.1. Saudi Arabia
      • 8.5.3.2. UAE
      • 8.5.3.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Device Type
    • 8.6.2. By Application
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Taiwan
      • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Medtronic
  • 10.2. Stryker
  • 10.3. Abbott
  • 10.4. B. Braun Melsungen AG
  • 10.5. Boston Scientific Corporation
  • 10.6. Cordis
  • 10.7. Edwards Lifesciences Corporation
  • 10.8. GE Healthcare
  • 10.9. Biosensors International Group, Ltd.
  • 10.10. Biotronik, Inc.

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key benefits for the stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations